Accumulating evidence highlights the pivotal role of mitochondria in cardiovascular diseases (CVDs). Understanding the molecular mechanisms underlying mitochondrial dysfunction is crucial for developing targeted therapeutics. Recent years have seen substantial advancements in unraveling mitochondrial regulatory pathways in both normal and pathological states and the development of potent drugs. However, specific delivery of drugs into the mitochondria is still a challenge. We present recent findings on regulators of mitochondrial dynamics and reactive oxygen species (ROS), critical factors influencing mitochondrial function in CVDs. We also discuss advancements in drug delivery strategies aimed at overcoming the technical barrier in targeting mitochondria for CVD treatment.

越来越多的证据凸显了线粒体在心血管疾病（CVD）中的关键作用。了解线粒体功能障碍的分子机制对于开发靶向疗法至关重要。近年来，在揭示正常和病理状态下的线粒体调节途径以及强效药物的开发方面取得了重大进展。然而，将药物特异性递送到线粒体中仍然是一个挑战。我们介绍了线粒体动力学和活性氧 (ROS) 调节因子的最新发现，这是影响 CVD 线粒体功能的关键因素。我们还讨论了旨在克服靶向线粒体进行 CVD 治疗的技术障碍的药物输送策略的进展。